Our approach

---

A better biomarker for residual cancer is needed to diagnosis cancer recurrence at an earlier stage. Molecular residual disease (MRD) detection using a liquid biopsy has been shown to be helpful in early detection of recurrence which saves lives through better overall survival. Despite the clear benefits, MRD detection is not the current standard of care. The main issues preventing wider use of MRD tests is the lack of regulatory approval and high cost. Overall, the goal is to get patients the treatment they need by correctly identifying those patients with residual cancer.

SentryDx determined the four main problems with current MRD tests.

1. False positives
2. False negatives
3. High cost
4. Lack of standardization

SentryDx identified the root cause of each problem.

1. False positives (DNA mismatch hybridization)
2. False negatives (Probability)
3. High cost (High amount of sequencing)
4. Lack of standardization (Personalized tests)

SentryDx developed a patent pending method which blocks the replication of normal DNA during PCR.

Why Block?

Blocking solves the root cause for all the problems with current MRD tests. Blocking changes the outcome of DNA mismatch hybridization from "false signal" to "no net change". Blocking reduces false negatives and reduces the cost through enrichment of the cancer DNA in the sample. Cancer DNA is rare, a little as 1 in 10,000. Blocking increases the percent of cancer in a sample from 0.01% to >99%. As a result, much less sequencing is needed to confidently determine the absence or presence of cancer DNA. Blocking is also a standardized test, which identifies the same common mutations used in companion diagnostic tests. Overall, SentryDx is able to reliably detect a single copy of cancer DNA at a low cost through our patent pending blocking method.